Developing and Characterization of Chemically Modified RNA Aptamers for Targeting Wild Type and Mutated c-KIT Receptor Tyrosine Kinases

2019 ◽  
Vol 63 (5) ◽  
pp. 2209-2228 ◽  
Author(s):  
Ala’a S. Shraim ◽  
Abdelrahim Hunaiti ◽  
Abdalla Awidi ◽  
Walhan Alshaer ◽  
Nidaa A. Ababneh ◽  
...  
2013 ◽  
Author(s):  
Normand Beaulieu ◽  
Helene Sainte-Croix ◽  
Claire Bonfils ◽  
Michael Mannion ◽  
Stephane Raeppel ◽  
...  

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18532-e18532
Author(s):  
Mathilde Cabart ◽  
Judith Raimbourg ◽  
Lisenn Lalier ◽  
Jaafar Bennouna ◽  
Francois Vallette

e18532 Background: EGFR tyrosine kinase inhibitors (EGFR TKI) have improved the therapeutic care of lung cancer patients but only a small sub-population of patients, namely those harboring EGFR-mutated tumors, benefit from this therapy. The observation that EGFR TKI enhance prognosis and quality of life in all patients when used as second line or maintenance treatment impelled us into the search of potential markers of the optimal introduction kinetics of EGFR TKI in the therapeutic scheme. Methods: We used lung cancer cell lines harboring either wild-type or mutated EGFR (NCI-H1650, NCI-H1975) to study the consequences of cisplatin treatment in vitro on the consecutive sensitivity to erlotinib. Results: Sub-lethal cisplatin pretreatment (3µM) enhances erlotinib toxicity in EGFR wild-type, but not EGFR mutated cells (A549 IC50 drops from 28 to 15µM for short-term or 12µM for long-term exposure). This correlates with EGFR activation following short-term or prolonged cisplatin treatment through the secretion of EGFR ligands. This activation of EGFR is concomitant to the decrease in other receptor tyrosine kinases phosphorylation including Met. Conclusions: The sensitivity of EGFR wild-type lung cancer cells to erlotinib in vitro is enhanced by cisplatin pretreatment. We identified potential markers of this sensitization, namely EGFR ligands, which serum level might be predicitive of the optimal efficiency of EGFR TKI. In vivo validation of these markers is under investigation. The concomitant decrease in other receptor tyrosine kinases phosphorylation suggests that the targeting of other receptor tyrosine kinases might potentiate EGFR TKI efficiency.


Cancer ◽  
2018 ◽  
Vol 125 (4) ◽  
pp. 586-600 ◽  
Author(s):  
Silke Appenzeller ◽  
Anja Gesierich ◽  
Alexander Thiem ◽  
Anita Hufnagel ◽  
Christina Jessen ◽  
...  

Cell ◽  
1991 ◽  
Vol 65 (1) ◽  
pp. 91-104 ◽  
Author(s):  
Masayuki Otsu ◽  
Ian Hiles ◽  
Ivan Gout ◽  
Michael J. Fry ◽  
Fernanda Ruiz-Larrea ◽  
...  

2017 ◽  
Vol 112 (3) ◽  
pp. 64a
Author(s):  
William M. Marsiglia ◽  
Huaibin Chen ◽  
Min-kyu Cho ◽  
Moosa Mohammadi ◽  
Nathaniel J. Traaseth

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4400-4400
Author(s):  
Kristy J. Arnoczky ◽  
Trent B. Marburger ◽  
Tamara Vukosavljevic ◽  
Michael A. Caligiuri ◽  
Susan P. Whitman

Abstract Ubiquitin (Ub)-dependent proteolysis is a highly controlled pathway that regulates almost all cellular processes by modulating the levels of key proteins. Several E3 Ub ligases are functionally abnormal in cancer. The E3 ubiquitin ligase, Casitas B-lineage lymphoma (CBL) protein, negatively regulates many receptor tyrosine kinases (RTKs) that are frequently over-expressed and/or constitutively activated (e.g., FLT3) in acute myeloid leukemia (AML). The CBL linker region, encoded in part by exon 8, lies between the tyrosine kinase binding and the RING finger domains and, mutations introduced into this linker region were previously shown to confer transforming ability. Herein, we describe novel splicing mutations in the c-CBL gene that lead to aberrant pre-mRNA processing in AML. DNA PCR revealed a splice site mutation whereby 14 nucleotides were deleted at the exon 8-intron 8 boundary in one CBL allele of the MOLM-13 cell line. Out of 18 patient samples, one primary AML blast sample had a 4 base pair deletion (16 bases upstream of the intron 7-exon 8 junction) which was replaced by a 12 base pair GC-rich insertion. We hypothesized that this mutation was an intronic splicing silencer element. RT-PCR/sequencing confirmed aberrant pre-mRNA processing in both the AML patient sample and MOLM-13 cells as they expressed a wild-type CBL transcript and an in-frame variant lacking exon 8. The splice variants are reminiscent of the oncogenic Cbl intragenic deletion mutation present in the murine pre-B cell line, p70Z. Such Cbl mutants are suggested to result in a structural alteration, allowing displacement of wild-type Cbl from the RTK complex thereby abrogating Cbl’s negative regulatory function. Thus it is possible that this mutant may enhance proliferation and survival of AML cells through attenuation of ubiquitin/proteosome-dependent degradation of receptor tyrosine kinases. Further investigation into the role of CBL and other players in the Ub-mediated proteolytic pathway is likely to provide additional insight into a subset of AML patients that in turn could lead to discovery of new therapeutic targets and strategies.


1999 ◽  
Vol 19 (11) ◽  
pp. 7870-7885 ◽  
Author(s):  
Nieves Movilla ◽  
Xosé R. Bustelo

ABSTRACT We report here the identification and characterization of a novel Vav family member, Vav-3. Signaling experiments demonstrate that Vav-3 participates in pathways activated by protein tyrosine kinases. Vav-3 promotes the exchange of nucleotides on RhoA, on RhoG and, to a lesser extent, on Rac-1. During this reaction, Vav-3 binds physically to the nucleotide-free states of those GTPases. These functions are stimulated by tyrosine phosphorylation in wild-type Vav-3 and become constitutively activated upon deletion of the entire calponin-homology region. Expression of truncated versions of Vav-3 leads to drastic actin relocalization and to the induction of stress fibers, lamellipodia, and membrane ruffles. Moreover, expression of Vav-3 alters cytokinesis, resulting in the formation of binucleated cells. All of these responses need only the expression of the central region of Vav-3 encompassing the Dbl homology (DH), pleckstrin homology (PH), and zinc finger (ZF) domains but do not require the presence of the C-terminal SH3-SH2-SH3 regions. Studies conducted with Vav-3 proteins containing loss-of-function mutations in the DH, PH, and ZF regions indicate that only the DH and ZF regions are essential for Vav-3 biological activity. Finally, we show that one of the functions of the Vav-3 ZF region is to work coordinately with the catalytic DH region to promote both the binding to GTP-hydrolases and their GDP-GTP nucleotide exchange. These results highlight the role of Vav-3 in signaling and cytoskeletal pathways and identify a novel functional cross-talk between the DH and ZF domains of Vav proteins that is imperative for the binding to, and activation of, Rho GTP-binding proteins.


Sign in / Sign up

Export Citation Format

Share Document